UK markets closed

Vera Therapeutics, Inc. (VERA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
45.54+2.10 (+4.83%)
At close: 04:00PM EDT
45.40 -0.14 (-0.31%)
After hours: 05:47PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 2.37B
Enterprise value 2.26B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)23.26
Enterprise value/revenue N/A
Enterprise value/EBITDA -24.49

Trading information

Stock price history

Beta (5Y monthly) 1.05
52-week change 3475.40%
S&P500 52-week change 322.38%
52-week high 350.78
52-week low 37.10
50-day moving average 342.89
200-day moving average 324.28

Share statistics

Avg vol (3-month) 31.07M
Avg vol (10-day) 31.01M
Shares outstanding 554.45M
Implied shares outstanding 654.45M
Float 839.88M
% held by insiders 17.95%
% held by institutions 184.63%
Shares short (15 Apr 2024) 46.31M
Short ratio (15 Apr 2024) 45.38
Short % of float (15 Apr 2024) 417.16%
Short % of shares outstanding (15 Apr 2024) 411.59%
Shares short (prior month 15 Mar 2024) 46.24M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-41.54%
Return on equity (ttm)-107.50%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-95.99M
Diluted EPS (ttm)-2.25
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)160.72M
Total cash per share (mrq)2.95
Total debt (mrq)53.71M
Total debt/equity (mrq)52.82%
Current ratio (mrq)7.71
Book value per share (mrq)2.29

Cash flow statement

Operating cash flow (ttm)-92.18M
Levered free cash flow (ttm)-62.13M